Prezista label
Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: risks likely to outweigh benefits
Drug 1
Drug 1 dose
800 mg darunavir once daily
Drug 1 effect
Cmin decreased 21%
Drug 2 dose
150 / 150 mg once daily
Drug 2 effect
Elvitegravir AUC decrease 20%, Cmin decrease 52%; Cobicistat AUC decrease 15-20%
Clinical Effects
Potential for decreased or increased elvitegravir, cobicistat, and / or darunavir effects
Management
Use alternative agents. One study supports clinical use of elvitegravir / cobicistat with darunavir 800 mg daily in treatment experienced patients.
Import ID
993
